Azafaros Announces Enrollment of First Patient in Phase 2 RA

RAINBOW study design enables rapid advancement into the company's planned Phase 3 efficacy trial Azafaros B.V. today announced that the first patient has been enrolled into its Phase 2 RAINBOW

Related Keywords

Brazil , Switzerland , Netherlands , Zeiten , Mecklenburg Vorpommern , Germany , United States , Curitiba , Paranár , United Kingdom , Swiss , Dutch , Gretchen Schweitzer , Porto Alegre , Marie Theresa Weickert , Stefan Klotter , Roberto Giugliani , Healthcare Products Regulatory Agency , Trophic Communications , Drug Administration , Leiden University , European Medicines Agency , Genetics Clinical Research Group , Daniel Almeida , Paediatric Neurologist , Medical Genetics Clinical Research Group , Hospital De Clinicas Porto Alegre , Lead Principal Investigator , Chief Executive Officer , Rare Pediatric Disease Designations , United States Food , Orphan Medicinal Product Designation , Innovation Passport , United Kingdom Medicines , Fast Track Designation , Orphan Drug Designations , Tay Sachs Diseases , Niemann Pick , Biogeneration Ventures , Stabile Ertr , Chart Profi Stefan Klotter , Blue Chips , Azafaros , Nnounces , Enrollment , First , Patient , Hase , Rainbow , Study , Valuating , 102 , Patients ,